



# LUND UNIVERSITY

## **IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.**

Landberg, Niklas; Hansen, Nils; Askmyr, Maria; Ågerstam, Helena; Lassen, Carin; Rissler, Marianne; Hansen, H H; Mustjoki, S; Järås, Marcus; Richter, Johan; Fioretos, Thoas

*Published in:*  
Leukemia

*DOI:*  
[10.1038/leu.2015.135](https://doi.org/10.1038/leu.2015.135)

2015

[Link to publication](#)

### *Citation for published version (APA):*

Landberg, N., Hansen, N., Askmyr, M., Ågerstam, H., Lassen, C., Rissler, M., Hansen, H. H., Mustjoki, S., Järås, M., Richter, J., & Fioretos, T. (2015). IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. *Leukemia*, 30(1), 255-258.  
<https://doi.org/10.1038/leu.2015.135>

*Total number of authors:*  
11

### **General rights**

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

1 **IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of**  
2 **chronic myeloid leukemia predicts therapy outcome**

3

4 Niklas Landberg<sup>1</sup>, Nils Hansen<sup>1</sup>, Maria Askmyr<sup>1</sup>, Helena Ågerstam<sup>1</sup>, Carin Lassen<sup>1</sup>,  
5 Marianne Rissler<sup>1</sup>, Henrik Hjorth Hansen<sup>2,3</sup>, Satu Mustjoki<sup>4</sup>, Marcus Järås<sup>1</sup>, Johan  
6 Richter<sup>5</sup>, and Thoas Fioretos<sup>1</sup>

7

8 <sup>1</sup>Department of Clinical Genetics, Lund University, Lund, Sweden

9 <sup>2</sup>Department of Hematology, St Olavs Hospital, Trondheim, Norway

10 <sup>3</sup>Department of Cancer Research and Molecular Medicine, Norwegian University of  
11 Science and Technology (NTNU), Trondheim, Norway

12 <sup>4</sup>Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology,  
13 University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital,  
14 Helsinki, Finland

15 <sup>5</sup>Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund,  
16 Sweden

17

18 **Running title:** IL1RAP as a prognostic marker in CML

19

20 **Key words:** chronic myeloid leukemia, leukemic stem cells, prognosis, tyrosine kinase  
21 inhibitors

22     **Conflicts of interest**

23     M.J. and T.F. are cofounders and have equity ownership in Cantargia AB (Ideon Medical  
24     Village, Lund, Sweden) formed with Lund University Bioscience AB. J.R. has stock  
25     options in Cantargia AB and has received honoraria from Novartis and Bristol-Myers  
26     Squibb. S.M. has received research funding from Novartis, Bristol-Myers and Squibb and  
27     Pfizer and honoraria from Novartis and Bristol-Myers and Squibb. The remaining  
28     authors declare no competing financial interests.

29

30     **Corresponding authors:**

31     Niklas Landberg, MD	38     Thoas Fioretos, MD, PhD
32     Address: Department of Clinical	39     Address: Department of Clinical
33     Genetics, Lund University, BMC C13,	40     Genetics, Lund University, BMC C13,
34     Klinikgatan 26, 221 84 Lund, Sweden	41     Klinikgatan 26, 221 84 Lund, Sweden
35     E-mail: niklas.landberg@med.lu.se	42     E-mail: thoas.fioretos@med.lu.se
36     Phone nr: +46 46 222 69 97	43     Phone nr: +46 46 222 45 95
37     FAX nr: +46 46 13 10 61	44     FAX nr: +46 46 13 10 61

45

## LETTER TO THE EDITOR

Chronic myeloid leukemia (CML) is characterized by the *BCR/ABL1* fusion gene formed by a t(9;22) chromosomal translocation. The t(9;22) is thought to arise in a hematopoietic stem cell (HSC) creating a hierarchically arranged leukemia with a subset of cells in the CD34<sup>+</sup>CD38<sup>low</sup> fraction comprising the primitive leukemia initiating cells, also termed leukemic stem cells (LSCs).<sup>1,2</sup> The treatment of CML was greatly improved with the introduction of tyrosine kinase inhibitors (TKIs) more than a decade ago, but not all patients respond optimally to initial treatment and even after obtaining a deep molecular remission, discontinuation of treatment is often followed by relapse.<sup>3-5</sup>

The LSC-burden of CML patients at diagnosis could potentially provide an important disease variable for predicting response to TKI treatment. We previously estimated the LSC-burden at diagnosis of CML by quantification of primitive CD34<sup>+</sup>CD38<sup>low</sup> *BCR/ABL1* positive cells, which was predictive of response to TKI therapy.<sup>6</sup> However, this procedure would be challenging to implement clinically because it requires both sorting of CD34<sup>+</sup>CD38<sup>low</sup> CML cells and fluorescent in situ hybridization (FISH) analysis to enumerate *BCR/ABL1* positive cells. Here, we aimed at establishing a flow cytometry-based protocol to estimate the LSC-burden at diagnosis by exploring the expression of cell surface markers reported to be upregulated on primitive CML CD34<sup>+</sup>CD38<sup>low</sup> cells.

Several markers have recently been proposed to be upregulated on candidate CML stem cells, including IL1RAP,<sup>7</sup> CD25 (IL2RA),<sup>8</sup> CD26 (DPP4),<sup>8</sup> CD123 (IL3RA),<sup>9</sup>, CD117(KIT),<sup>10</sup> and ST2 (IL1RL1 or IL33R).<sup>11</sup> Of these markers, only CD26 and IL1RAP, a co-receptor of the interleukin 1 receptor (IL1R1) with unknown function in normal and malignant hematopoiesis, have so far been proven to separate *BCR/ABL1* positive from negative cells within the CD34<sup>+</sup>CD38<sup>low</sup> fraction.<sup>7,8</sup> Here, we first used a

staining protocol to simultaneously analyze the expression of these seven markers in bone marrow aspirates from five CML patients and two normal bone marrows (NBM). The LSC-containing CML CD34<sup>+</sup>CD38<sup>low</sup> compartment was defined as shown in Figure 1a. We found that IL1RAP, CD25 and CD26 were distinctly upregulated on primitive CML cells relative to corresponding cells in NBM, whereas the other markers showed a variable expression pattern or were expressed also on CD34<sup>+</sup>CD38<sup>low</sup> NBM cells (Figure 1b and Supplemental Table 1). CD123, CD117 and IL1R1 were all expressed on the immature CML CD34<sup>+</sup>CD38<sup>low</sup> cells but showed expression also on the normal HSC. In contrast to a recent study reporting low ST2 expression on CML CD34<sup>+</sup>CD38<sup>low</sup> cells,<sup>11</sup> this marker could only be detected in one of five CML patients using the same antibody, possibly because of a lower sensitivity of our flow cytometry protocol. Thus IL1RAP, CD25 and CD26 were specifically expressed on CML CD34<sup>+</sup>CD38<sup>low</sup> cells compared to corresponding normal cells.

To study the expression of LSC markers in more detail, IL1RAP, CD25 and CD123 were chosen for further analysis using an optimized panel of antibodies. As CD25 and CD26 displayed similar expression patterns in primitive CML cells (Figure 1c), consistent with previous studies,<sup>8</sup> we included only CD25 in the staining protocol. Instead, we selected CD123 since antibodies targeting this receptor currently are being evaluated as a therapy in CML.<sup>9</sup> These three markers were analyzed in a cohort of 21 CML patients included in the NordCML006 study in which patients were randomized to receive treatment either with imatinib or dasatinib.<sup>12</sup> A summary of patient data is provided in Supplementary Table 2. Using the optimized protocol, we obtained a clear separation of both IL1RAP positive and CD25 positive cells within the CML CD34<sup>+</sup>CD38<sup>low</sup> compartment, whereas CD123 expression failed to divide cells into distinct positive and negative cell populations (Figure 2a). In NBM, we did not observe

expression of IL1RAP or CD25 in the CD34<sup>+</sup>CD38<sup>low</sup> population, while CD123 was weakly expressed (Supplementary Figure 1). When analyzing co-expression of IL1RAP and CD25 in the CML CD34<sup>+</sup>CD38<sup>low</sup> compartment, we found one population co-expressing IL1RAP and CD25 and one expressing only IL1RAP. No cells were found to express only CD25 (Figure 2b). Although the cell fractions expressing IL1RAP and CD25 showed a significant correlation (Spearman's Rho 0.8558,  $p < 0.0001$ ), IL1RAP was present on a consistently larger fraction of CML CD34<sup>+</sup>CD38<sup>low</sup> cells (mean of difference 25.62%, CI 95% 15.81-35.44,  $p < 0.0001$ ).

To further delineate the difference between cells expressing IL1RAP and CD25, we correlated the flow cytometry data on IL1RAP and CD25 expression from the current study to previously reported *BCR/ABL1* FISH data on the CML CD34<sup>+</sup>CD38<sup>low</sup> population from the same patients.<sup>6</sup> IL1RAP expression showed a strong correlation with *BCR/ABL1* positivity in the CML CD34<sup>+</sup>CD38<sup>low</sup> fraction ( $r = 0.8078$ ,  $p < 0.0001$ ), with a slope of regression line close to 1 ( $Y = 0.8876X - 6.6$ ) (Figure 2c). This indicates that almost all CD34<sup>+</sup>CD38<sup>low</sup> *BCR/ABL1* positive cells express IL1RAP and that the *BCR/ABL1* negative cells lack IL1RAP. Only a weak correlation was seen between *BCR/ABL1* positive cells and CD25 expression ( $r = 0.4532$ ,  $p = 0.0391$ ) with a slope of regression of 0.36 ( $Y = 0.3584X + 2.6$ ), indicating that CD34<sup>+</sup>CD38<sup>low</sup> *BCR/ABL1* positive cells often lack CD25 expression (Figures 2d). We then used a previously described Flow-FISH sorting technique to sort CD34<sup>+</sup>CD38<sup>low</sup> cells according to CD25 expression and evaluated the fraction *BCR/ABL1* positive cells in four CML patients. We found that of the CD25 expressing cells, a mean of 98% were *BCR/ABL1* positive cells (ranging between 94-100%), whereas the CD25 negative population of the same patients still contained a mean of 85% *BCR/ABL1* positive cells (range between 46-99%). Consistent with our previous findings,<sup>7</sup> sorted IL1RAP positive CD34<sup>+</sup>CD38<sup>low</sup> cells contained a

great majority (99%) of *BCR/ABL1* positive cells (Supplementary Figure 2), whereas IL1RAP negative cells were almost all *BCR/ABL1* negative (5%). Taken together, these data show that IL1RAP is a marker for *BCR/ABL1* positive cells in the CML CD34<sup>+</sup>CD38<sup>low</sup> fraction, whereas CD25 is only expressed on a subfraction of *BCR/ABL1* positive cells.

The response of CML to TKI treatment is currently monitored by cytogenetic analyses and real time quantitative reverse polymerase chain reaction (RQ-PCR) analysis of *BCR/ABL1* transcript levels.<sup>4</sup> However, so far no easily implementable laboratory-based method is available to estimate the LSC-burden at diagnosis as a possible predictor of treatment response. We therefore investigated whether IL1RAP or CD25 expression in the CML CD34<sup>+</sup>CD38<sup>low</sup> compartment, as a measure of the LSC-burden at diagnosis, could provide clinically relevant prognostic information. In our previous study, the presence of ≥80% *BCR/ABL1* positive cells by FISH in the CD34<sup>+</sup>CD38<sup>low</sup> fraction at diagnosis of CML was used to define a group of patients with 'high' LSC-burden, whereas <80% were designated as 'low' LSC-burden.<sup>6</sup> Based on IL1RAP expression, we used a similar definition, i.e. patients were classified as IL1RAP<sup>low</sup> (n=13, defined as <80% of the CD34<sup>+</sup>CD38<sup>low</sup> cells expressing IL1RAP) or IL1RAP<sup>high</sup> (n=8, ≥80% of CD34<sup>+</sup>CD38<sup>low</sup> cells expressing IL1RAP). Following this subdivision, we investigated if the two groups differed in the probability of achieving optimal response as defined by the European Leukemia Net (ELN) guidelines, following TKI treatment (Supplementary Table 3).<sup>4</sup> All IL1RAP<sup>low</sup> and 7 of 8 IL1RAP<sup>high</sup> patients achieved *BCR/ABL1* transcript levels ≤10% within 3 months. However, IL1RAP<sup>low</sup> patients had a higher chance of reaching transcript levels <1% after 6 months (p=0.0475), a definition of optimal response according to ELN.<sup>4</sup> Since this cohort consisted of mainly optimal responders at 3 months, we looked at even deeper levels of molecular and cytogenetic response, previously shown to predict long-term outcome at

146 this time point.<sup>13,14</sup> Interestingly, IL1RAP<sup>low</sup> patients (13 out of a total of 21) had a higher  
147 chance of achieving complete cytogenetic response (CCyR) (p=0.0009) and major  
148 molecular response (MMR; *BCR/ABL1* transcript levels  $\leq 0.1\%$ ) after 3 months (p=0.023)  
149 (Supplementary Table 3). No significant correlations were seen between IL1RAP  
150 expression and Sokal or Hasford risk scores. Altogether, this suggests that IL1RAP  
151 expression as a measure of LSC-burden at diagnosis predicts cytogenetic and molecular  
152 response to TKI treatment although larger prospective studies are needed before such  
153 measurement can be implemented clinically.

154 Previously, light scattering properties together with CD34 and CD45  
155 expression have been shown to differentiate between *BCR/ABL1* positive and negative  
156 CML CD34<sup>+</sup>CD38<sup>low</sup> cells.<sup>15</sup> Using that protocol, it was shown that the LSC-burden at  
157 diagnosis could predict CCyR after 1 year of treatment as well as MMR after 1.5 years.  
158 No correlations were made to response after 3 months of therapy. Other investigators  
159 have used CD26 as a marker for primitive CML cells and showed a correlation with  
160 leukocyte counts at diagnosis but not with Sokal or Hasford risk scores, possible  
161 association to cytogenetic and molecular response were not reported.<sup>8</sup> In contrast to our  
162 results, the authors could not detect overexpression of IL1RAP on primitive CML cells in  
163 all patients. Most likely, the difference in the two studies is a result of different  
164 sensitivities of the two assays to detect IL1RAP expression. All patients in our study  
165 clearly expressed IL1RAP; even in a patient in which FISH analysis of sorted  
166 CD34<sup>+</sup>CD38<sup>low</sup> cells revealed <1% *BCR/ABL1* positive cells, a fraction of cells expressed  
167 IL1RAP (patient no 10, Supplementary Table 2).

168 In conclusion, we identified IL1RAP, CD25 and CD26 as the most specific  
169 markers for primitive CML cells relative to corresponding normal cells and demonstrate  
170 that the percentage of IL1RAP expressing cells within the CD34<sup>+</sup>CD38<sup>low</sup> compartment



can be used to predict the response to TKI treatment. The described flow cytometry-based protocol may become a valuable prognostic tool in the management of CML patients.

Supplementary information is available at Leukemia's website

### **Acknowledgements**

We thank all investigators of the NordCML006 study for sharing samples and clinical data. This work was supported by the Swedish Cancer Society, the Swedish Children's Cancer Foundation, the Swedish Research Council, the Inga-Britt and Arne Lundberg Foundation, the Gunnar Nilsson Cancer Foundation, the Medical Faculty of Lund University, the strategic research program BioCARE, the Finnish Cancer Institute, and the Academy of Finland.

## 184    **References**

- 185    1    Ren R. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous  
186        leukaemia. *Nat Rev Cancer* 2005; **5**: 172–183.
- 187    2    Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid  
188        leukemia. *Leukemia* 2010; **24**: 1823–1833.
- 189    3    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a  
190        therapeutic agent for chronic myeloid leukemia. *Blood* 2005; **105**: 2640–2653.
- 191    4    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF *et al.*  
192        European LeukemiaNet recommendations for the management of chronic myeloid  
193        leukemia: 2013. *Blood* 2013; **122**: 872–884.
- 194    5    Mahon FX, Etienne G. Deep Molecular Response in Chronic Myeloid Leukemia: The  
195        New Goal of Therapy? *Clinical Cancer Research* 2014; **20**: 310–322.
- 196    6    Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T *et al.*  
197        Impact of malignant stem cell burden on therapy outcome in newly diagnosed  
198        chronic myeloid leukemia patients. *Leukemia* 2013; **27**: 1520–1526.
- 199    7    Jaras M, Johnels P, Hansen N, Ågerstam H, Tsapogas P, Rissler M *et al.* Isolation and  
200        killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-  
201        1 receptor accessory protein. *PNAS* 2010; **107**: 16280–16285.
- 202    8    Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzi G, Willmann M *et al.*  
203        Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid  
204        leukemia. *Blood* 2014; **123**: 3951–3962.
- 205    9    Nievergall E, Ramshaw HS, Yong ASM, Biondo M, Busfield SJ, Vairo G *et al.*  
206        Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes  
207        CML progenitor and stem cells. *Blood* 2014; **123**: 1218–1228.
- 208    10   Florian S, Sonneck K, Hauswirth AW, Krauth M-T, Schernthaner G-H, Sperr WR *et al.*  
209        Detection of molecular targets on the surface of CD34+/CD38– stem cells in various  
210        myeloid malignancies. *Leuk Lymphoma* 2006; **47**: 207–222.
- 211    11   Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E *et al.* BCR-  
212        ABL-Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from  
213        Chronic Myeloid Leukemia Patients. *Cancer Research* 2014; **74**: 2669–2676.
- 214    12   Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T  
215        *et al.* Dasatinib induces fast and deep responses in newly diagnosed chronic  
216        myeloid leukaemia patients in chronic phase: clinical results from a randomised  
217        phase-2 study (NordCML006). *European Journal of Haematology* 2014.  
218        doi:10.1111/ejh.12423.
- 219    13   Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM *et al.* Assessment of  
220        BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting  
221        Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine

- 222 Kinase Inhibitors. *Journal of Clinical Oncology* 2012; **30**: 232–238.
- 223 14 Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A *et al.* Early  
224 molecular and cytogenetic response is predictive for long-term progression-free  
225 and overall survival in chronic myeloid leukemia (CML). *Leukemia* 2012; **26**: 2096–  
226 2102.
- 227 15 Janssen JJWM, Deenik W, Smolders KGM, van Kuijk BJ, Pouwels W, Kelder A *et al.*  
228 Residual normal stem cells can be detected in newly diagnosed chronic myeloid  
229 leukemia patients by a new flow cytometric approach and predict for optimal  
230 response to imatinib. *Leukemia* 2011; **26**: 977–984.
- 231

## Figure legends

### Figure 1

Flow cytometry analysis of stem cell surface marker expression in CML. (a) Gating algorithm used to determine progenitor and stem cell compartments. (b) Representative histograms showing expression of IL1RAP, CD25, CD26, CD123, IL1R1, CD117 and ST2 in the CD34<sup>+</sup>CD38<sup>low</sup> compartment of a CML patient and a NBM. Isotype control (red line) and staining antibody (blue line). (c) Dotplots of co-expression of CD25 and CD26 in the CD34<sup>+</sup>CD38<sup>low</sup> compartment in 5 CML patients, isotype control (red) and staining antibody (blue).

### Figure 2

Expression of IL1RAP, CD25 and CD123 in CD34<sup>+</sup>CD38<sup>low</sup> cells from 21 CML patients. (a) Histograms of IL1RAP, CD25 and CD123 in the CD34<sup>+</sup>CD38<sup>low</sup> compartment of a representative CML patient. Isotype control (red line) and staining antibody (blue line). (b) Co-expression of IL1RAP and CD25 in CD34<sup>+</sup>CD38<sup>low</sup> cells. (c) Flow cytometry assessed IL1RAP expression in CD34<sup>+</sup>CD38<sup>low</sup> cells shows a strong correlation to previously reported FISH data on *BCR/ABL1* expression from 21 CML patients. (d) Flow cytometry assessed CD25 expression in CD34<sup>+</sup>CD38<sup>low</sup> cells shows a weaker correlation to the previously reported FISH data on *BCR/ABL1*. (e) CD34<sup>+</sup>CD38<sup>low</sup> cells from four CML patients sorted according to CD25 expression and analyzed with fluorescence in situ hybridization with probes detecting *BCR/ABL1*. Mean values are plotted, error bars show range.

Figure 1





Figure 2



**Supplementary information to:**

**IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome**

Niklas Landberg<sup>1</sup>, Nils Hansen<sup>1</sup>, Maria Askmyr<sup>1</sup>, Helena Ågerstam<sup>1</sup>, Carin Lassen<sup>1</sup>,  
Marianne Rissler<sup>1</sup>, Henrik Hjorth Hansen<sup>2,3</sup>, Satu Mustjoki<sup>4</sup>, Marcus Järås<sup>1</sup>, Johan  
Richter<sup>5</sup>, and Thoas Fioretos<sup>1</sup>

<sup>1</sup>Department of Clinical Genetics, Lund University, Lund, Sweden

<sup>2</sup>Department of Hematology, St Olavs Hospital, Trondheim, Norway

<sup>3</sup>Department of Cancer Research and Molecular Medicine, Norwegian University of  
Science and Technology (NTNU), Trondheim, Norway

<sup>4</sup>Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology,  
University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital,  
Helsinki, Finland

<sup>5</sup>Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund,  
Sweden

## **Supplementary materials and methods**

### **Patient material**

All patient samples were obtained after informed, written consent and the study was performed in accordance to the declaration of Helsinki. Bone marrow aspirates from CP CML patients were obtained before initiation of TKI treatment, and mononuclear cells were isolated using Lymphoprep (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Enrichment for CD34 expressing cells was performed using MACS-beads according to the manufacturers instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were cryopreserved until the time of analysis. Samples of peripheral blood and normal bone marrow (NBM) were processed in a similar way. In total, 26 diagnostic CML samples were included in the study. Twenty-one of these samples were from patients included in the NordCML006 study in which patients were randomized to receive treatment either with imatinib or dasatinib.<sup>1</sup> A summary of patient data included in the present study is provided in Supplementary Table 2.

### **Flow cytometry analysis and cell sorting**

Analysis of cell surface protein expression was performed on a FACS Aria IIu (BD Biosciences, Franklin Lakes, New Jersey, USA). Antibodies used for staining (targeting CD34, CD38, IL1RAP, CD25, CD26, CD123, CD117, IL1R1 and ST2) were purchased from BD Biosciences, BioLegend (San Diego, California, USA) and R&D Systems (Minneapolis, Minnesota, USA); a full list of antibodies used is provided in Supplementary Table 4. One of the monoclonal anti-IL1RAP antibodies (used in combination with anti-CD25 and anti-CD123 antibodies) was purchased from R&D Systems (clone 89412) and conjugated to Biotin (BD Biosciences) by Innovagen AB (Lund, Sweden). Non-specific Fc-receptor binding was blocked by incubation with Fc-blocking IgG1 kappa from murine



myeloma, clone MOPC-21 (Sigma Aldrich, Saint Louis, Missouri, USA), and cells were stained in phosphate-buffered saline (PBS) (Thermo Fisher Scientific, Waltham, Massachusetts, USA) with 2% fetal calf serum (FCS) (Stemcell Technologies, Cambridge, United Kingdom). Cell lines BV173, KU812 and KG1 (DSMZ, Braunschweig, Germany) were used as positive controls for CD34, CD38, IL1RAP, CD25, IL1R1, CD117 and ST2. Peripheral blood from a healthy donor was used as a positive control for CD26. Isotype controls were used at concentrations corresponding to the staining antibodies and fluorescence minus one (FMO) controls did not differ from isotype controls (data not shown). Propidium iodide (BD Biosciences) or Draq7 (Biostatus, Shepshed, United Kingdom) were used as viability markers.

The 80% of cells with the highest CD38 expression were defined as positive and the bottom 5% with the lowest CD38 expression were defined as low, as previously described.<sup>2</sup> In one patient (patient 9) the lowest 2% were classified as CD38 low due to the atypical expression pattern of CD34 and CD38 (Supplementary Figure 3). Gates used to define positivity for a cell surface marker were set to include <1% false positive cells based on isotype controls. There were five exceptions due to poor separation and gates for these samples (patients 3, 7, 9, 18 and 19) were set manually (Supplementary Figure 4). To compare flow cytometry data from this study to the data from FISH analysis previously performed in the NordCML006 study, two different gating algorithms to define CD34<sup>+</sup>CD38<sup>+</sup> and CD34<sup>+</sup>CD38<sup>low</sup> cells were used to match the two different gating strategies used for cell sorting at the different study centers (Figure 1a and Supplementary Figure 5).<sup>2</sup> A Flow-FISH sorting technique previously described was used to sort cells and analyze *BCR/ABL1* content by FISH.<sup>3</sup>

68    **Statistical analysis**

69    Statistical analyzes were performed using Graphpad Prism 6 (GraphPad Prism Inc, La  
70    Jolla, California, USA). Two-sided non-parametrical methods for correlations (Mann-  
71    Whitney U, Spearman's rank test) and tests of difference in distribution (Chi-square test)  
72    were used as deemed appropriate. In total, 26 patients were analyzed, 21 of whom had  
73    been included in the NordCML006 study and for whom detailed clinical data were  
74    available.<sup>1</sup> The remaining five patients were diagnosed at Skåne University Hospital and  
75    were not enrolled in the NordCML006 study.

76   **References**

- 77   1   Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T *et*  
78       *al.* Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid  
79       leukaemia patients in chronic phase: clinical results from a randomised phase-2  
80       study (NordCML006). *European Journal of Haematology* 2014.  
81       doi:10.1111/ejh.12423.
- 82   2   Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T *et al.* Impact  
83       of malignant stem cell burden on therapy outcome in newly diagnosed chronic  
84       myeloid leukemia patients. *Leukemia* 2013; **27**: 1520–1526.
- 85   3   Jaras M, Johnels P, Hansen N, Ågerstam H, Tsapogas P, Rissler M *et al.* Isolation and  
86       killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1  
87       receptor accessory protein. *PNAS* 2010; **107**: 16280–16285.

88

## Supplementary tables

**Supplementary Table 1.** Expression pattern of seven cell surface markers in the CD34<sup>+</sup>CD38<sup>+</sup> and CD34<sup>+</sup>CD38<sup>low</sup> compartments of five chronic myeloid leukemia patients and two normal bone marrow samples.

	CML CD34 <sup>+</sup> cells		NBM CD34 <sup>+</sup> cells	
	CD38 <sup>low</sup>	CD38 <sup>+</sup>	CD38 <sup>low</sup>	CD38 <sup>+</sup>
<b>IL1RAP</b>	100% (5/5)	100% (5/5)	0% (0/2)	100% (2/2)
<b>CD25</b>	100% (5/5)	0% (0/5)	0% (0/2)	0% (0/2)
<b>CD26</b>	100% (5/5)	0% (0/5)	0% (0/2)	0% (0/2)
<b>CD123</b>	80% (4/5)	60% (3/5)	50% (1/2)	100% (2/2)
<b>CD117</b>	100% (5/5)	100% (5/5)	100% (2/2)	100% (2/2)
<b>IL1R1</b>	100% (5/5)	100% (5/5)	50% (1/2)	100% (2/2)
<b>ST2</b>	20% (1/5)	20% (1/5)	0% (0/2)	0% (0/2)

Abbreviations: CML, chronic myeloid leukemia; NBM, normal bone marrow

95 **Supplementary Table 2.** Percentage of IL1RAP and CD25 positive cells in the  
96 CD34<sup>+</sup>CD38<sup>low</sup> cell populations, percentage of *BCR/ABL1* positive cells determined  
97 by fluorescence in situ hybridization in the CD34<sup>+</sup>CD38<sup>low</sup> cell populations, treatment  
98 regimen, and the *BCR/ABL1* transcript levels at follow up in 21 newly diagnosed CML  
99 patients.

Patient	CD34 <sup>+</sup> CD38 <sup>low</sup> cells			Drug	BCR/ABL1 on IS (%)	
	IL1RAP <sup>+</sup> (%)	CD25 <sup>+</sup> (%)	BCR/ABL1 <sup>+</sup> (%)		3 months	6 months
1	36.4	26.3	43	IM	0.7391	0.1011
2	24.9	13.6	79	IM	4.7036	2.0153
3	84.1	41.8	93	DAS	3.7763	1.3264
4	85.9	38.7	87	DAS	0.7807	0.0198
5	19.7	10.8	69	IM	0.4734	0.1957
6	74.3	25.9	83	DAS	0.0076	0.0000
7	93.2	22.8	97	IM	2.6932	2.9056
8	12.1	5.36	66	IM	0.0634	0.0184
9	57.8	22.4	66	DAS	0.0000	0.0077
10	4.78	2.81	1	DAS	0.0526	0.0166
11	22	16.5	16	IM	3.2648	0.3582
12	11.1	6.49	35	DAS	0.2248	0.0699
13	28.6	21.5	45	IM	1.2560	0.0406
14	34.6	13.7	93	DAS	0.0125	0.0000
15	50	15.7	48	IM	0.0730	0.0115
16	86.1	72.9	89	IM	4.3748	0.2785
17	28.5	20.5	57	DAS	0.1161	0.0776
18	91.2	42.6	98	IM	0.2326	0.0324
19	90.5	23.4	88	DAS	1.9723	0.0000
20	91.4	56.7	92	IM	1.3660	11.2385
21	87.6	76.2	75	IM	89.5865	22.8885

100 Abbreviations: IS, International Scale; IM, imatinib; DAS, dasatinib

101

**Supplementary Table 3.** Clinical response rates in CML patients stratified into IL1RAP<sup>low</sup> and IL1RAP<sup>high</sup> based on expression as a measure of LSC-burden at diagnosis.

	<i>BCR/ABL1</i> ≤10% at 3 months		CCyR at 3 months		<i>BCR/ABL1</i> ≤0.1% at 3 months		<i>BCR/ABL1</i> ≤1% at 6 months	
	IL1RAP expression status at diagnosis <sup>a</sup>							
	Low	High	Low	High	Low	High	Low	High
Yes	13	7	13	4	6	0	12	4
No	0	1	0	2	7	8	1	4
P-value	ns		<0.001		0.023		0.048	

<sup>a</sup>IL1RAP<sup>low</sup> was defined as <80% of CD34<sup>+</sup>CD38<sup>low</sup> cells expressing IL1RAP and IL1RAP<sup>high</sup> as ≥80% of CD34<sup>+</sup>CD38<sup>low</sup> cells expressing IL1RAP.

Abbreviations: CCyR, complete cytogenetic remission; ns, not significant

109 **Supplementary Table 4.** Complete list of antibodies used for flow cytometry  
110 analysis.

Target	Fluorochrome	Clone	Company
CD34	BV421	Mono-mouse IgG1 581	BD Biosciences
CD38	BV605	Mono-mouse IgG1 HB7	BD Biosciences
IL1RAP	APC	Mono-mouse IgG1 89412	R&D Systems
CD25	PE-CF594	Mono-mouse IgG1 M-A251	BD Biosciences
CD26	FITC	Mono-mouse IgG2a L272	BD Biosciences
CD123	BV711	Mono-mouse IgG1 9F5	BD Biosciences
CD117	Pe-Cy7	Mono-mouse IgG1 140D2	BioLegend
IL1R1	PE	Poly -goat IgG	R&D Systems
ST2	PE	Mono-mouse IgG1	R&D Systems
CD34	APC	Mono-mouse IgG1 581	BioLegend
CD38	APC-H7	Mono-mouse IgG1 HB7	BD Biosciences
CD25	PE	Mono-mouse IgG1 M-A251	BD Biosciences
IL1RAP	(Biotin)	Mono-mouse IgG1 89412	R&D Systems
Biotin	BV421	(Streptavidin)	BD Biosciences
Isotype	BV421	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	BV605	Mono-mouse IgG1 X40	BD Biosciences
Isotype	APC	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	PE-CF594	Mono-mouse IgG1 X40	BD Biosciences
Isotype	FITC	Mono-mouse IgG2a MOPC-173	BioLegend
Isotype	BV711	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	Pe-Cy7	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	PE	Poly -goat IgG	R&D Systems
Isotype	PE	Mono-mouse IgG1 97203	BioLegend
Isotype	APC	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	APC-H7	Mono-mouse IgG1 MOPC-21	BD Biosciences
Isotype	PE	Mono-mouse IgG1 97203	BioLegend
Isotype	BV711	Mono-mouse IgG1 MOPC-21	BioLegend
Isotype	(Biotin)	Mouse Isotyp - Biotin, Clone 11711	R&D Systems
Viability	Draq7	-	Biostatus
Viability	PI	-	BD Biosciences

111

## **Supplementary figure legends**

### **Supplementary Figure 1.**

Expression of IL1RAP, CD25 and CD123 in the CD34<sup>+</sup>CD38<sup>+</sup> and CD34<sup>+</sup>CD38<sup>low</sup> cells of two normal bone marrow samples. Isotype control (red line) and staining antibody (blue line).

### **Supplementary Figure 2**

CD34<sup>+</sup>CD38<sup>low</sup> cells from a CML patients sorted according to IL1RAP expression and analyzed with fluorescence in situ hybridization with probes detecting *BCR/ABL1*.

### **Supplementary Figure 3**

The left plot shows the gates used to determine CD34<sup>+</sup>CD38<sup>+</sup> progenitor population and CD34<sup>+</sup>CD38<sup>low</sup> stem cell containing population. The right plot shows gates used to determine CD34<sup>+</sup>CD38<sup>+</sup> progenitor population and CD34<sup>+</sup>CD38<sup>low</sup> stem cell containing population for patient no 9. The 2% cells with lowest CD38 expression were defined as CD38<sup>low</sup> in this patient.

### **Supplementary Figure 4**

Gates for IL1RAP and CD25 expression were set to include less than 1% of the isotype control. For five samples this was not possible, instead gates to determine the size of the positive fraction were set manually as shown here. Cell populations depicted are CD34<sup>+</sup>CD38<sup>low</sup>, isotype control in red and stained samples in blue.





135 **Supplementary Figure 5**


136 Gating algorithm used for chronic myeloid leukemia samples collected in Finland,  
137 matching the gates used when sorting these cells for FISH.

138

Supplementary Figure 1




Supplementary Figure 2




# Supplementary Figure 3

Standard gates



Patient 9



# Supplementary Figure 4


**Patient 3**

**Patient 7**

**Patient 9**


**Patient 18**

**Patient 19**



**Patient 7**

**Patient 18**



— = isotype  
— = stain

Supplementary Figure 5

